{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:03:49Z","timestamp":1790726629709,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103456","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:45:09Z","timestamp":1774514709000},"page":"103456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemophilia and hereditary angioedema: parallel therapeutic advances in genetic diseases of serine protease pathways"],"prefix":"10.1016","volume":"10","author":[{"given":"Massimo","family":"Cugno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-3897","authenticated-orcid":false,"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103456_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103456_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","article-title":"Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus","volume":"154","author":"Reshef","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rpth.2026.103456_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.anai.2025.05.018","article-title":"Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database","volume":"135","author":"Castaldo","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rpth.2026.103456_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.103456_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmed.2008.12.001","article-title":"C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress","volume":"15","author":"Cugno","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.rpth.2026.103456_bib6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103456_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM200208223470820","article-title":"Bradykinin-mediated angioedema","volume":"347","author":"Nussberger","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2018.09.004","article-title":"Angioedema and emergency medicine: from pathophysiology to diagnosis and treatment","volume":"59","author":"Depetri","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2026.103456_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rpth.2026.103456_bib10","doi-asserted-by":"crossref","DOI":"10.1159\/000550750","article-title":"Ageing with haemophilia: comorbidities in focus","author":"R\u00fchl","year":"2026","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.rpth.2026.103456_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaip.2023.12.046","article-title":"Comorbidities in angioedema due to C1-inhibitor deficiency: an Italian survey","volume":"12","author":"Zanichelli","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rpth.2026.103456_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/bloodadvances.2025017220","article-title":"Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder","volume":"10","author":"Rodriguez Espada","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103456_bib13","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1182\/blood.V89.9.3213","article-title":"Activation of the coagulation cascade in C1-inhibitor deficiencies","volume":"89","author":"Cugno","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103456_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13223-020-00437-x","article-title":"Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review","volume":"16","author":"Levy","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.rpth.2026.103456_bib15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaip.2020.01.007","article-title":"Life expectancy in Italian patients with hereditary angioedema due to C1-inhibitor deficiency","volume":"8","author":"Perego","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rpth.2026.103456_bib16","doi-asserted-by":"crossref","unstructured":"Pierce GF, Lusher JM, Brownstein AP, Goldsmith JC, Kessler CM. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA 261:3434\u20133438.","DOI":"10.1001\/jama.1989.03420230088032"},{"key":"10.1016\/j.rpth.2026.103456_bib17","doi-asserted-by":"crossref","unstructured":"Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 323:1800\u20131805.","DOI":"10.1056\/NEJM199012273232604"},{"key":"10.1016\/j.rpth.2026.103456_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0038-1657536","article-title":"Recombinant factor IX","volume":"78","author":"White","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103456_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198003063021002","article-title":"Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor","volume":"302","author":"Gadek","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2023.04.017","article-title":"Hereditary angioedema: a review of the current and evolving treatment landscape","volume":"11","author":"Betschel","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rpth.2026.103456_bib21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands\u2019 diseases","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103456_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM197208312870907","article-title":"Tranexamic acid therapy in hereditary angioneurotic edema","volume":"287","author":"Sheffer","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib23","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM197612232952602","article-title":"Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities","volume":"295","author":"Gelfand","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib24","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.103456_bib25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.rpth.2026.103456_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103456_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib31","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMe2405299","article-title":"New therapies for type 1 and type 2 hereditary angioedema","volume":"391","author":"Ameratunga","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMc2415164","article-title":"Platelet-targeted gene therapy for hemophilia A with inhibitor history","volume":"392","author":"Eapen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-based therapy for hereditary angioedema","volume":"392","author":"Cohn","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib37","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine\u2014personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103456_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3324\/haematol.2023.284095","article-title":"Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children","volume":"109","author":"Andersson","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.103456_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102312","article-title":"Driving towards precision medicine for angioedema without wheals","volume":"104","author":"Germenis","year":"2019","journal-title":"J Autoimmun"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:18:03Z","timestamp":1790723883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926001147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926001147"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103456","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia and hereditary angioedema: parallel therapeutic advances in genetic diseases of serine protease pathways","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103456"}}